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Abstract
With advancing technology and the consequent shift towards an increasing application of molecular genetic techniques (e.g.,
microarrays, next-generation sequencing) with the potential for higher resolution in specific contexts, as well as the
application of combined testing strategies for the diagnosis of chromosomal disorders, it is crucial that cytogenetic/
cytogenomic services keep up to date with technology and have documents that provide guidance in this constantly evolving
scenario. These new guidelines therefore aim to provide an updated, practical and easily available document that will enable
genetic laboratories to operate within acceptable standards and to maintain a quality service.
Introduction
Chromosomal analysis has been a key tool in genetic ana-
lysis with conventional, as well as molecular, cytogenetics
playing a crucial role over the years in many genomic
disorders and in many laboratory settings. The overall
application of these techniques by clinical genetics labora-
tories led to the need for harmonising cytogenetic practices
and produce guidelines applicable throughout Europe. This
was first achieved, in 2009, by the Permanent Working
Group ‘Cytogenetics and Society’ European Cytogenetics
Association and updated in 2012 [1]. Those documents
have given the guidance on generic, as well as specific
aspects of diagnostic guidelines and covered constitutional
cytogenetics, acquired cytogenetics, microarrays and
molecular-based techniques. However, given the advances
in genetic technology and the shift towards molecular
genetic techniques (e.g., microarrays, next-generation
sequencing), as well as the application of combined strate-
gies for the diagnosis of chromosomal disorders, it is
essential that the cytogenetic/cytogenomic guidelines keep
up to date. These new guidelines therefore aim to provide
an updated, practical and easily available document that
may be used by European Clinical Genetics laboratories.
These guidelines take into account good laboratory practice
documents, the existing external quality assessment
schemes, accreditation procedures and protocols from dif-
ferent countries, as well as international policy documents
(see Appendix A) and therefore, they apply unless over-
ridden by national/federal laws, regulations and/or stan-
dards. The following standards should be considered as
minimum acceptable criteria for constitutional chromoso-
mal/cytogenomic analysis and therefore, any laboratory
consistently operating below the minimum standard may be
at risk of failing to maintain a quality service. Specific
guidelines referring to cytogenomic analysis in acquired
disorders are included elsewhere [2, 3].
This document is organised in two sections: general and
specific guidelines. General guidelines address fundamental
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criteria to follow when providing cytogenomic testing
regardless of the methodology applied. Specific guidelines
supplementing these general guidelines include recom-
mendations for each technique/methodology in particular.
Both sections provide minimum acceptable criteria for
sample preparation, analysis and reporting, as well as the
limitations of the tests.
Cytogenomics is used herein as a general term that
encompasses conventional, as well as molecular cytoge-
netics (fluorescence in situ hybridisation (FISH), micro-
arrays) and molecular-based techniques. Specific
designations are used when needed, otherwise the global
term applies. Please note that non-invasive prenatal testing
(NIPT) is not included in these guidelines as this is a
screening test not a diagnostic test. Recommended practice
guidelines regarding reporting NIPT results have recently
been described by Deans et al. [4].
The use of terms such as ‘should’, ‘must’ or ‘essential’
are mandatory requirements, whereas the use of terms such
as ‘may’ and ‘could’ are recommended, but not mandatory.
General guidelines
This section addresses fundamental criteria to follow when
providing diagnostic testing regardless of the methodology
applied.
Service requirements regarding equipment, facilities,
staff and diagnostic workload must comply with ISO15189
and/or ISO17025. All pre- and post-analytical procedures
should also follow written protocols/standard operating
procedures (SOP) in compliance with ISO15189 and/or
ISO17025.
Pre-analytical recommendations
Whenever a cytogenomic abnormality is suspected by the
clinician as underlying a given patient’s condition/disorder
a cytogenomic analysis should be considered. As with all
genetic testing, informed consent for genetic testing should
be given; whether a copy if this written consent is required
by the laboratory will depend on National policy. Therefore,
genetic counselling and communication, pre- as well as
post-testing, is of utmost importance. Appropriate expert
counselling may be provided by a medical doctor, nurse or a
clinical laboratory specialist trained in the field of genetics.
Patients must be informed about the scope, principle,
resolution and limitations of the tests available for their
specific context/situation. The possibility of incidental
findings, (unrelated to the clinical question but nevertheless
of importance for the individual’s health) and of unin-
formative or uncertain results should be addressed. Coun-
selling is also vital after testing to aid the correct
interpretation of the results and ensure the patient can truly
make an informed decision.
Although local policies might differ throughout coun-
tries, the following list is given as guidance to delineate the
type of referral indications and of the expected scope of a
cytogenomics service:
Main clinical indications for prenatal diagnosis
- Abnormal foetal ultrasound;
- High-risk maternal serum screening/NIPT result indi-
cating an increased risk of a chromosomally abnormal
foetus;
- Parental chromosome rearrangement, mosaicism or
previous aneuploidy;
- Previous livebirth/stillbirth with a chromosome
abnormality;
- Possible foetal mosaicism detected by prior prenatal
study;
- Familial monogenic disorder (i.e., CF, Noonan syn-
drome, etc).
Main clinical indications for postnatal diagnosis
- Abnormal clinical phenotype;
- Multiple congenital abnormalities;
- Clinically significant abnormal growth – short stature,
excessive growth, microcephaly, macrocephaly;
- Primary or secondary amenorrhoea or ovarian
insufficiency;
- Ambiguous genitalia;
- Infertility of unknown aetiology;
- Sperm abnormalities – azoospermia or severe
oligospermia;
- A malformed foetus or stillbirth of unknown aetiology;
- Third and subsequent miscarriage(s): products of
conception;
- Significant familial history of chromosome
rearrangements;
- Significant familial history of intellectual disability (ID)
of possible chromosomal origin where it is not possible to
study the affected individual;
- Carriership for an X-linked recessive disorder in a
female.
Other postnatal indications may include
- Parental follow-up of a chromosomal abnormality or
variant detected in a pre- or postnatal foetal/child’s sample;
- Delineation of an abnormal cytogenomic result;
- Refractory epilepsy for mosaicism exclusion.
When deciding which methodology to apply, the specific
referral indication and the advantages and limitations of
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each technique must be taken into account (e.g., resolution,
reporting time) (Table 1).
Sample preparation
Depending on the referral reason, the tissue types and
sample preparation may vary. However, there are general
recommendations that should be considered when preparing
samples for cytogenomic analysis.
Cultures set-up for prenatal samples should be performed
in duplicate or independently, where possible. For chorionic
villus samples (CVSs) it is recommended to establish and
analyse long-term cultures (LTCs, cytotrophoblast and
mesenchymal cells), even if short-term cultures (STCs;
cytotrophoblast cells) are in place, to allow for mosaicism
exclusion when needed (see below). In embryo develop-
ment, the mesenchymal cells more closely represent the
foetal genotype than cytotrophoblast cells and therefore
long-term CVS cultures are more likely to represent the
foetal karyotype than short-term cells/cultures [5, 6]. Back
up cultures of prenatal samples should be kept until the final
report is written, and when practicable, the possibility of
freezing viable cells, as well as fixed cell pellets should be
available for cases that may require further cytogenomic or
molecular analysis. For postnatal analysis, blood samples
may be stored in the refrigerator for up to 5 days and a
second culture initiated if required.
DNA extraction methods, should either be automated or
require minimal tube–tube transfers and produce DNA that
is reliable for use in the techniques applied thereafter if
possible. There must be internal criteria for ascertaining the
DNA quality and quantity, as well as the minimum
threshold for suitability for a given test. Precautions must be
in place to minimise PCR product contamination therefore a
separation of pre- and post-PCR areas is required. Controls
must be included in each PCR set-up to identify DNA or
PCR product contamination.
The most critical issues regarding sample preparation
involve ensuring, as much as possible, that the samples are
correctly identified (i.e., sample verification) and suitable for
the technique used, as well as minimising the possibility of
misdiagnosis. For prenatal samples, a minimum of two cul-
tures should be set-up and analysed, although for follow-up of
an abnormal rapid result only a single culture is required,
providing the results are concordant. Maternal cell con-
tamination (MCC) and confined placental mosaicism (CPM),
in the case of CVS, may greatly increase the possibility of
misdiagnosis. According to Hsu and Benn [7], three cultures
should be analysed for mosaicism exclusion. MCC may be
due to the presence of blood in amniotic fluid (AF) samples or
of maternal decidua in CVS, for instance. In the latter case, it
is essential that the CVS is thoroughly cleaned and maternal
decidua removed prior to DNA preparation and/or culture set-
up. Nevertheless, whenever the origin of the prenatal sample,
which is female is in doubt, genotype analysis of a maternal
(blood) sample should be performed. Specifically, genotype
analysis is recommended for poor quality CVS where pla-
cental villi cannot be confidently identified and for AF pellets
exhibiting a significant* amount of blood staining (*as
determined by the laboratory).
To avoid misdiagnosis due to CPM, it is recommended
that heterogeneous cell populations are analysed.
This may be done using several villi, instead of just
one, for the preparation of the DNA pools and/or
cultures. It is also recommended that the same pool of
chopped or digested villi are used for molecular-based
analysis and culture set-up to minimise discrepant
results [8].
Table 1 Methods used in cytogenomic analysis, their resolution and limitations
Method Resolution Limitations
Karyotyping 5–10Mb Cannot detect: small rearrangements below the resolution; nucleotide
variants; mosaicism < 10%a; UPDb
FISH ~100 kb Limited to the probes used (targeted analysis);
Cannot detect: nucleotide variants; mosaicism < 10%c; UPD
Array-based techniques
chromosomal microarray SNP-based
array
~20–200 kb Cannot detect: balanced rearrangement; mosaicism < 10%d; nucleotide
variants; the nature of a structural aberration; independent cell lines;
heterochromatic markers; triploidy (exception SNP array); UPD (exception
SNP array)
CNV detection in whole-exome
sequencing
100 bp (exonic regions) –
~150 kb (genome wide)e
Cannot detect: balanced rearrangement; mosaicism < 18%f; the nature of the
structural aberration; independent clones/cell lines
aHsu and Benn [7]; Hook [36]
bUniparental disomy
cWiktor and van Dyke [37]; Ballif et al. [38]; Mascarello et al. [39]
dVermeesch et al. [23]; Ballif et al. [38]
ePfundt et al. [32]
fPagnamenta et al. [40]
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A checking procedure should be in place for all critical
transfer steps (i.e., setting up or when transferring details of
identity).
Analysis
Laboratories must ensure that the staff have the skills and
expertise, as well as collaborations and supervisory
arrangements, to perform the tests and correctly interpret the
findings. Appropriate training for the types of samples to be
analysed must be ensured and written criteria (SOP) for
classification of observations and interpretation of results
should be in place.
All analyses should be performed by qualified profes-
sionals trained in Clinical Laboratory Genetics and be
independently checked by a second trained member of staff,
who could be a technician or a clinical laboratory geneticist,
the latter also being responsible for signing out the report.
An independent check by a ‘blind’ analysis is recommended
as this prevents any bias.
According to the methodology used, specific require-
ments for the analysis are recommended (see section Spe-
cific guidelines).
Reporting
The reporting of results should be standardised as far as
possible, unambiguous, informative and clear to read by the
non-specialist in order to be understood by the recipient/
clinician. A summary banner should be given that includes
all the relevant results. All reports should include an inter-
pretation of the results and answer the clinical referral/
question. Long reports should be avoided as this detracts
from the clarity of the results. Methodology and limitations
of the test should not take prominence in a report as they
can detract from the results and interpretation.
Reporting times should be kept as short as possible and
should take into account the reason for referral and level of
urgency (see Table 2).
The results should be given using the most recent
International System for Human Cytogenomic
Nomenclature (ISCN) [9], where practicable. Human Gen-
ome Variation Society (HGVS) nomenclature (http://www.
HGVS.org/varnomen) should be used when applicable.
HUGO Gene Nomenclature Committee (HGNC) gene
names should be used in ISCN, where applicable. The
results can be tabulated if the result is complex. Single-cell
anomalies and heteromorphisms should not be included in
the ISCN in a diagnostic report.
All reports, regardless of the methodology used, should
comply with ISO15189 and include the following infor-
mation [10]:
- Reason for referral/clinical indication for the test;
- Date of sampling, date of receipt and the date of report;
- Patient identification using two different identifiers
(IDs), i.e., full name and birth date; Twins IDs must be
clearly distinct;
- Gender of the patient (postnatal referrals – essential for
sex chromosome referrals);
- Unique sample identifier;
- Name of referring clinician and hospital;
- Laboratory identification;
- Tissue examined (i.e., DNA isolated from cultured
fibroblasts);
- A clear summary of the results (ISCN, HGVS or as a
summary statement) (i.e., not hidden within the text);
- A written description of the results including the sex of
the patient (for prenatal samples stating the genetic sex is
optional);
- A written interpretation of the results (understandable
by a non-specialist);
- Relating the result to the referral reason and/or
answering the clinical question;
- Specification of which kit/probe (QF-PCR/MLPA/
FISH) or array platform is used and stating the respective
test limitations;
- Patient identification should be present on each page;
- Name and signature of one or two authorised persons,
which may include the Section Head/Clinical Laboratory
Geneticist. The signature may be generated electronically or
manually;
- Pagination (i.e., page 1 of 1 or page 1 of 2).
Table 2 Recommended
reporting times (calendar days)
for 90% of the referrals
Prenatal aneuploidy testing by FISH /QF-PCR/MLPA 4 days
Amniotic fluid and CVS analysis on cultured or uncultured cells by karyotyping and/or
genome-wide array analysis
14 days
Lymphocyte cultures 28 days
Products of conception/foetal skin (where pregnancy is not ongoing) 28 days
Urgenta lymphocyte, cord blood cultures 7 days
Postnatal array analysis 10 days (urgent)
28 days (other)
These apply in the absence of specific National Guidelines
aURGENT – referrals where the result will have immediate implications for patient management
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In addition to the information stated above, reports of
abnormal results should also include, when appropriate, the
following:
- A clear written description of the abnormality;
- Whether the result is consistent with the clinical find-
ings, and/or an indication of the expected phenotype/syn-
drome (e.g., ‘consistent with ___ syndrome’, or ‘associated
with ___ syndrome’, or ‘indicative of ___ syndrome’);
- In case of intragenic imbalances (detected by array,
MLPA and/or CNV in exome data), the HGNC gene
symbol should be mentioned and it is recommended to also
specify the reference transcript (representing either the
longest known transcript and/or the most clinically relevant
transcript);
- Any follow-up tests required to confirm the results and/
or suspected diagnosis, preferably stating, which samples
(i.e., heparin or EDTA blood, buccal swab, etc.) are
required for these specific tests;
- Assessment of recurrence, when appropriate;
- Prenatal diagnosis in future pregnancies, if appropriate;
- Recommendation for genetic counselling;
- Comment stating, where applicable to the disorder,
‘Please ensure the karyotype record appears in the child’s
own notes’ (after delivery for prenatal samples);
- Request for follow-up of family members at risk of the
abnormality, starting with closest available relatives;
- Minimum threshold used for reporting ‘abnormal’
results.
The presence of MCC or pseudomosaicism should
always be noted on the laboratory record but should not be
commented upon on the final report unless relevant for
result interpretation. For mosaic results found in CVS, CPM
should be discussed in the report, if applicable. AF mosaic
reports should consider that the proportions of the abnormal
and normal cell lines may be different in foetal tissue(s).
The need for pre- or postnatal follow-up samples and/or
parental samples should always be made clear, where
appropriate.
Specific guidelines
The following recommendations supplement the general
guidelines (see section General guidelines) and give more
specific guidance on constitutional cytogenomic analysis
performed using the techniques currently available.
Karyotyping
All karyotyping should be carried out using a banding
technique, with G-banding being the most widely used
technique. The laboratory has to ensure that whichever
banding technique is used it has to achieve the required
banding quality (see Table 3). ISCN (2016) [9] defines five
levels of banding and Table 3 gives the minimum quality
levels that must be met to report a ‘normal’ result.
Full analysis must be completed and checked by the
supervisor ensuring the minimum quality levels appropriate
for the referral reason are met. Where it is not possible to
achieve the minimum quality for the referral reason, and no
abnormality is detected, the report should be suitably qua-
lified while not encouraging a repeat invasive procedure
when this is not clinically justified. Targeted analysis may
be appropriate to investigate abnormalities identified by
another method, for example, to establish the chromosome
abnormality and recurrence risk for prenatal cases identified
as having a chromosome aneuploidy by QF-PCR.
The laboratory should have written protocols for analy-
sis. Incomplete/broken metaphases should not be included
in the analysis. Metaphase analysis must involve a com-
parison of every set of homologues (including sex chro-
mosomes), band by band. If one homologue pair is involved
Table 3 Minimum G-banding
quality according to the reason
for referral
Reason for referral Minimum G-banding quality
(QAS) a
Confirmation of aneuploidy QAS 2a ⇔ < 300 bphs
Exclusion of known large structural rearrangements QAS 3 ⇔ 300 bphs
Identification and exclusion of small expected structural rearrangements;
routine prenatal specimen preparations
QAS 4 ⇔ 400 bphsb
Prenatal specimen abnormal ultrasound referrals (in the absence of array-
based analysis)
QAS 5 ⇔ 550 bphsb
Routine postnatal specimen preparations QAS 6 ⇔ 550 bphsb
bphs bands per haploid set
aQAS score – see ACC Professional guidelines for clinical cytogenetics v1.04 (2007; http://www.acgs.uk.
com/media/765607/acc_general_bp_mar2007_1.04.pdf)
bSNP-based array or other molecular techniques/SNP-based array or other molecular techniques may be
more applicable for some of these referral categories
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in an overlap with another chromosome, the pair of
homologues should be independently scored in another
metaphase to ensure there is no structural rearrangement.
Therefore, additional cells have to be counted and analysed
to complete the analysis. For guidance on the number of
metaphases that should be analysed for each type of tissue
see Table 4. In general, a minimum of two cells must be
fully analysed (at the minimum quality for the respective
referral reason), although in practice more metaphases are
counted and analysed to clear any crossovers. If mosaicism
is clinically indicated or suspected, an extended analysis
and/or cell count must be performed (see Table 4 for
number of cells and also the latest ISCN for definition of a
clonal abnormality). Laboratories may choose to analyse or
count more cells routinely than the minimum given in
Table 4 to exclude mosaicism for all referrals – not just
where suspected from the referral information. Internal
reports should include the number of cells analysed and
counted, with relevant details provided.
A report can be issued upon detection of an imbalance in
the proband whether or not the sample was referred indi-
vidually or with parental blood samples. Comments on the
clinical significance may be made if a phenotypic associa-
tion is supported in the published literature, otherwise it is
appropriate to report the anomaly as having unknown sig-
nificance. Polymorphic variants that have been previously
reported as harmless should be excluded from the report (to
avoid confusion for the non-specialist) and only docu-
mented in the patient’s laboratory record [5]. Cytogeneti-
cally visible polymorphic variants include variants
involving heterochromatin (variant size), satellite size,
pericentric inversions (heterochromatic or euchromatic
regions) [e.g., 1qh+/qh-, 9qh+/qh-, 16qh+/qh-, acrocentric
p+ or p-, Yqh+/qh-, inv(9)(p11q13), inv(2)(p11.2q13)] and
also euchromatic variants (e.g., located on 4p16, 8p23.1,
9p12, 9q13-q21.12, 15q11.2, 16p11.2) [11].
Mosaicism or pseudomosaicism should also be excluded
from the report if it is likely to be a cultural artefact after
appropriate work-up (see Gardner and Amor) [5]. Dis-
tinction between a cultural artefact and true mosaic aber-
ration is not always easy, so application of general rules
together with consideration of the clinical referral need to be
kept in mind when reaching a decision (please refer to ISCN
[9], EUCROMIC study [12] or the ACC collaborative study
[13]). If XX/XY mosaicism (in prenatal samples) is >10%
or is level III, further investigations should be done (e.g.,
quantitative fluorescence-polymerase chain reaction (QF-
PCR)) before reporting.
Chromosome instability syndromes
As this type of syndromes is rare and challenging both in
terms of analysis and interpretation, it is recommended that
these cases are referred to experienced/reference labs with
proven expertise. Classic chromosome breakage disorders
include Ataxia telangiectasia (AT), Bloom syndrome, Fan-
coni anaemia, Nijmegen breakage syndrome (NBS),
Roberts’ syndrome, Immunodeficiency–Centromeric
instability–Facial anomalies (ICF) syndrome and Mosaic
Variegated Aneuploidy (MVA) [5, 14]. Other syndromes
involving defective DNA replication/repair (e.g., Cockayne
syndrome and Xeroderma pigmentosum) are not amenable
to cytogenetic methods of confirmation. Although cytoge-
netic studies are often the first step in making a diagnosis,
continuing research has led to identification and cloning of
putative disease genes. Therefore it is recommended that
molecular testing is considered instead of/or to supplement
cytogenetic analysis, in particular now that targeted exome
sequence analysis is available in some diagnostic
laboratories.
When analysing breakage syndrome referrals, it is
essential that sufficient numbers of metaphases are exam-
ined in order to ensure that any chromosomal damage
detected is significant. Clastogen studies must only be
undertaken with appropriate negative matched control
samples and, if available, positive matched control samples.
All control and test samples should be processed, cultured
and harvested in parallel. Controls should be appropriately
matched (e.g., sex, age etc.). The patient and control sam-
ples should be analysed blindly.
For Bloom syndrome, it is recommended that 20 harle-
quin banded metaphases are examined as some patients
have a population of cells with a normal sister chromatid
Table 4 Minimum number of metaphases to be analysed according to
tissue type
Sample Referral/result Minimum
analyseda
Additional cells
countedb
Prenatal Routine 2 (2 cultures)c 0d
Postnatal Routine 2e 0
Pre- and
postnatal
Mosaicism exclusion
or single-cell
anomaly detection
2 28f
aAnalysed (banded metaphases where every set of homologues without
any crossovers are evaluated in their entirety). (In practice more
metaphase are analysed to clear any crossovers – see section
Karyotyping)
bCounted (metaphases where the number of centric chromosomes and/
or the presence/absence of a specific cytogenetic feature is evaluated)
cQF-PCR and one culture in case of aneuploidy testing
dExtra cells may be counted to exclude mosaicism or a single-cell
anomaly
eACC Professional guidelines for clinical cytogenetics v1.04 (2007;
http://www.acgs.uk.com/media/765607/acc_general_bp_mar2007_1.
04.pdf) and Hastings et al. [1]
fHsu and Benn [7] and Hook [36]
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exchange (SCE) frequency. The laboratory should have an
internal record of the SCE frequencies found when the same
methods are applied to a range of normal control samples.
As the BLM gene has been identified in association with
Bloom syndrome, molecular testing to confirm the cytoge-
netic result is now possible.
Analysis of at least 50, but preferably 100 metaphases, is
recommended for Fanconi anaemia to exclude the possibi-
lity of a somatic variant, which is common in these patients.
To ensure the efficacy of the clastogen used SCE levels
should be analysed in negative cases. The mean breakage
per aberrant cell and the mean breakage per normal cell
should be calculated. Referral to molecular analysis of
complementation groups, or targeted exome sequencing is
also recommended for abnormal results.
For AT and NBS, the aberration frequency in irradiated
cultures should be calculated by scoring 50–100 meta-
phases. As some patients display an intermediate response
to irradiation, screening of 50 banded metaphases for rear-
rangements, involving the T-cell antigen receptor loci on
chromosomes 7 and 14, should also be carried out. As the
ATM and NBN genes have been cloned (and associated with
AT and NBS, respectively) molecular analysis for con-
firmatory purposes should be suggested for patients with
positive cytogenetic and/or radio sensitivity assays.
Roberts’ syndrome referrals require scoring of 50 block
(Leishman/Giemsa stained) or C-banded metaphases for
centromere puffing and tramline chromosomes. Fifty ban-
ded metaphases should be counted for evidence of
aneuploidy.
Fifty banded metaphases should also be scored in ICF
syndrome cases for anomalies of the heterochromatic
regions of chromosomes 1, 9 and 16 and for multi-branched
configurations.
MVA is characterised by mosaic aneuploidies, pre-
dominantly trisomies and monosomies, involving multiple
different chromosomes together with normal cells. Some-
times these are single-cell anomalies but a proportion of
metaphases with aneuploidy > 25% is required to define the
disorder (OMIM #257300).
Fluorescence in situ hybridisation
FISH can be applied to interphases and/or metaphases, for a
variety of clinical applications. Usually it addresses a spe-
cific clinical question and therefore it is important that the
clinical reason for testing is provided on the referral form.
Single probe or multiple chromosome probes can provide
reliable results in different clinical situations (Tables 5
and 6). Whole chromosome paints (wcp) have a limited
application and are only applicable for metaphase FISH
analysis to identify large imbalances or rearrangements ( >
5–10Mb). In most instances, the clinical laboratory
geneticist will decide whether FISH or another testing
method is more appropriate depending on the referral rea-
son. Interphase FISH could be used as a method of choice in
instances where rapid test results are required, for example,
to detect trisomy 21 or sex chromosome constitution in
newborns. Interphase FISH is also used for aneuploidy
testing (trisomies 13, 18, 21 and sex chromosome aneu-
ploidies) as an alternative method to QF-PCR or multiplex
ligation-dependent probe amplification (MLPA) in prenatal
diagnosis or for routine investigation of pregnancy losses.
Metaphase FISH, on the other hand, is a method of
choice for the detection of submicroscopic balanced rear-
rangements and can be used for chromosome imbalances
when targeted proband/family follow-up investigations of
abnormalities detected by array analysis are required.
FISH can be performed pre- or postnatally. Postnatally,
FISH can be used on virtually every tissue (e.g., lympho-
cytes obtained after blood withdrawal, skin tissue, urine
specimens, buccal swabs, tissue derived from products of
conception, etc.). Prenatally, FISH can be performed on
either direct slides from uncultured (interphase) or cultured
amniocytes, as well as on CVS slides of STC (trophoblast
cells) or LTC (mesenchymal cells). Blood staining in an AF
sample should be noted as these samples may contain MCC
(see section Quantitative fluorescence-polymerase chain
reaction). In case of suspected mosaicism or to rule out
CPM, FISH on STC, as well as LTC slides can be
performed.
Individual FISH probes that are used repeatedly in rou-
tine diagnostics should be validated to ascertain the upper
(with known abnormal sample(s)) and lower thresholds
(with normal sample(s)) for reporting a normal or an
abnormal result [15]. Sufficient numbers of metaphases, or
Table 5 Applications of FISH analysis
Type of FISH
analysis
Applications of FISH analysis
Rapid prenatal
FISH
High risk of chromosome aneuploidy or
recurrent microdeletion (e.g., abnormal
ultrasound);
late gestation referral.
Evaluation/characterisation of
Interphase FISH Numerical abnormalities;
Duplications;
Deletions;
Sex chromosome constitution;
Mosaicism;
Gene amplification.
Metaphase FISH Marker chromosome;
Unknown material attached to a chromosome;
Rearranged chromosome(s);
Suspected gain or loss of a chromosome
segment;
Mosaicism.
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nuclei from cultured or uncultured cells must be analysed
depending on the probe type to ensure the statistical validity
of the result. Signals must be scored (Table 6) by two
independent analysts or may be confirmed by another
technique. There may be variation in probe signals both
between slides (depending on age, quality, etc. of meta-
phase spreads) and within a slide. Where a deletion or a
rearrangement is suspected, adequate hybridisation effi-
ciency can be confirmed either by the presence of a signal
on the normal chromosome or if a control probe is provided
in the probe mix. Depending on the sensitivity and speci-
ficity of the probe and on the number of cells scored, the
possibility of mosaicism should be considered, and com-
ments made where appropriate (Table 5). FISH analysis
may be the most appropriate method of confirming sus-
pected mosaicism if a suitable probe is available to assess
levels of mosaicism or chimerism of different cell lines.
Low-level mosaicism (10%) should be interpreted with
caution as this is within the limitations of the assay. In some
instances, more than one tissue type should be investigated
(e.g., if Pallister–Killian syndrome or trisomy 8 mosaicism
is suspected). The laboratory geneticist may decide that
fewer cells than indicated are analysed in cases where
screening for a specific abnormality is the main indication
for the study (e.g., checking for a known familial abnorm-
ality) or when an abnormality is detected but there are no
more cells available. The test should be repeated when
hybridisation results are not optimal. Most FISH results
should be accompanied by a karyotype analysis, except
when performed as follow-up test after array analysis or
when discrepancies are found between the findings and the
reason of referral.
FISH results should be related to the karyotyping or array
results, when available, and can be reported together with a
standard cytogenetic observation or array result (and com-
bining both in the ISCN), or as a stand-alone test result.
Normal FISH results should be reported within the text but
do not need to be included in the ISCN. Abnormal FISH
results should always be reported using the latest ISCN
nomenclature and with the designation of the clone name
(preferentially) or the locus designation (accession number,
gene name or D-number). The probe manufacturer should
also be provided. Internal reports should include the number
of cells scored and the hybridisation details. Contiguous
probes (contigs) may be reported following ISCN, i.e,
reporting all the contigs separated by single slant lines or if
only one contig probe for a specific chromosome is given in
the ISCN the full contig position should be described in the
report. Complex FISH results can be tabulated or given as a
summary result instead of using ISCN. Mosaic findings
should be related to the referral indication, where
appropriate.
It should be made clear that FISH analysis does not
substitute a complete cytogenomic analysis, provides
information solely on the locus of the probe used and its
limitations arise from the limitations of those probes (e.g.,
whether the probe localisation is within or flanking the
gene, cross hybridisation with other positions in the gen-
ome). Furthermore, normal results from highly repetitive
sequence probe analysis should be interpreted carefully due
to the possibility of individuals with rare polymorphisms
involving those sequences.
Care needs to be taken in interpreting interphase FISH
results. The signal in interphase cells can be variable,
therefore > 50 cells, must be examined. It should be noted
that this analysis is only able to detect a subset of
abnormalities and may be incomplete or misleading in the
absence of a karyotype analysis (e.g., der(21;21) or a sex
chromosome rearrangement).
Caution should be taken when interpreting rearrange-
ments using wcp probes results, and it should be performed
in conjunction with banding studies or after an abnormal
array result. It should be noted that the resolution of chro-
mosome paint probes is at best 5 Mb. Small rearrangements
may not be detected because wcp probes may not be uni-
formly dispersed across the full length of the target chro-
mosome. Chromosome paints cannot be used to ascertain
precise breakpoints.
In the case of single target probe results, i.e., locus-
specific identifier (LSI), the number of cells scored needs to
be in accordance with the sensitivity and specificity of the
probe used for analysis – usually five metaphases is
Table 6 Minimum criteria for analysing FISH results according with probe type
Probe type Analysis Additional comments
Locus-specific identifier (LSI)
probes
5
metaphases
Score to confirm or exclude an abnormality (e.g., in case of suspected microdeletion syndrome or
identification of a marker chromosome)
Multiprobe analysis 3
metaphases
Per probe. Scored to confirm a normal signal pattern. Confirmation is advisable for abnormal signal
patterns if no control probe is present
Interphase analysis for
aneuploidy testing
≥50 cells For each probe set
Interphase analysis to detect
mosaicism
≥100 cells For each probe set
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adequate. Microduplications may not be definitely identified
by FISH analysis; in cases where a microduplication is
suspected, confirmation by alternative methodologies (e.g.,
molecular analysis) is required.
Quantitative fluorescence-polymerase chain
reaction
QF-PCR analysis of microsatellite markers is widely used
for the detection of common aneuploidies in prenatal, foetal
tissue and new born blood samples. The approach has sig-
nificant economy of scale, detects triploidy and mosaicism
and genotypes the sample, allowing for identification of
MCC, twin pregnancies and chimeras. For prenatal samples,
it is recommended that chromosomes 13, 18 and 21 are
always tested. If the sex chromosomes are not routinely
tested, it is recommended that these are included for samples
where ultrasound anomalies are suggestive of monosomy X
(Turner syndrome). QF-PCR analysis is a diagnostic, tar-
geted test and does not require confirmation by another
approach. However, karyotype analysis should be under-
taken following identification of aneuploidy to identify
structural rearrangements. Where these are identified or
where karyotype analysis of the original material is not
possible, karyotype analysis of parental samples is indicated
to assess the recurrence risk. QF-PCR analysis may be used
as a stand-alone test for samples that are not at risk of other
chromosome abnormalities. For prenatal samples referred
with ultrasound abnormalities and a normal QF-PCR result,
subsequent array analysis is recommended.
It is recommended that tri/tetra/penta/hexanucleotide
repeat markers are used as these have fewer stutter peaks.
Dinucleotide repeat markers are acceptable if stutter peaks
are included in the analysis. Sufficient markers (at least
four markers per chromosome) should be included in QF-
PCR assays to minimise uninformative results and
reporting delays. Assays should be designed to cover the
length of the chromosome and to avoid clustering of
markers. New markers that have not been previously
reported for QF-PCR aneuploidy diagnosis should be
validated by testing a minimum of 100 chromosomes (the
equivalent to 50 unrelated DNA samples) to ensure they
are not located in a common copy number variant (CNV).
Unpublished primers should be checked and validated to
ensure the primers sequences are not affected by common
Single nucleotide polymorphisms (SNPs). Aneuploid
samples should be included in all validations to ensure the
correct chromosome location. It is recommended that
home-made kits are batch tested using at least a trisomy
and a normal DNA sample to ensure consistent assay
quality.
If the PCR cycle number is changed, the use of an
appropriate trisomy control is recommended to ensure that
biallelic ratios are maintained. Alleles must be clearly
separated. Either peak height or peak area ratios may be
used, if validated. It is recommended that both the elec-
trophoretogram and allele peak ratios are analysed to
identify low-level cell lines. To ensure the quality of the
data, both minimum and maximum peak heights should be
established. In line with current practice, it is recom-
mended that allele peak ratios are calculated by dividing
the peak height or area of the shorter length allele by that
of the longer length allele. Preferential amplification of
the shorter length allele is a feature of QF-PCR and the
normal and abnormal biallelic ratio ranges reflect this.
Although there is a requirement for testing laboratories to
validate/verify the biallelic ratio bins, normal ratios are
generally between 0.8 and 1.4, whereas those representing
trisomy are < 0.65 or > 1.8. Inconclusive ranges lie
between the abnormal and normal bins. For non-
polymorphic markers that are not subject to preferential
amplification, such as sex chromosome sequences TAF9L
and AMELOGENIN, a narrower allele range may be
appropriate. It is recommended that allele ratios that
indicate the different sex chromosome aneuploidies are
determined.
To interpret a result as normal at least two informative
marker results consistent with a normal biallelic pattern
are required per chromosome, with all other markers
uninformative. However, it is acceptable to report a
single-marker result that has a normal biallelic pattern and
all other markers uninformative as consistent with a nor-
mal chromosome complement, provided the report states
that the result is based on a single-marker result and that
this result must be confirmed. Abnormal polymorphic
marker results either exhibit three different alleles in a
1:1:1 ratio or biallelic 1:2 or 2:1 ratios (see above). To
interpret a result as abnormal (trisomy), at least two
informative marker results should be consistent with
trisomy with all the other markers uninformative. It is
unacceptable to interpret a single-marker result as
abnormal as this may represent a rare CNV or other
polymorphism (see below).
To identify monosomy X, one or more paralogous
markers (located on the X chromosome and an autosome,
e.g., TAF9L) must be used in addition to polymorphic X
chromosome counting markers and at least two Y
chromosome-specific sequences. In the absence of para-
logous markers, definitive diagnosis of monosomy or a
deletion is not possible.
Where more than one sample is processed, it is recom-
mended that sample identity of abnormal results is con-
firmed prior to reporting. This may be done by repeat PCR
of the DNA (where samples are prepared in isolation), re-
extraction and re-testing of the sample, or maternal geno-
type analysis.
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For heavily blood-stained samples, sexing is recom-
mended and if the sample is female, maternal genotype
analysis should be performed to establish the origin
of the genotype. The aneuploid status of samples exhi-
biting significant MCC, characterised by inconclusive
allele ratios and/or the maternal genotype present at a high
level, should not be determined. In these cases, the foetal
genotype, must not be stated or reported. CVS should be
expertly dissected to minimise MCC. Up to 2% of AF
samples will exhibit significant MCC and are
usually blood stained. In these cases, a QF-PCR result
from uncultured fluid will not be available and analysis
of cultured cells is recommended. It is recommended
that an uninformative or ‘unsuitable sample’ report is
issued.
When reporting a trisomy QF-PCR result, the name and
location of informative markers should be listed to define
the trisomic region. For monosomy X results, the name and
location of paralagous markers should be given. The
laboratory should have written procedures for reporting
other sex chromosome abnormalities, e.g., XXX, XXY,
XYY.
If a meiotic non-disjunction is indicated by the results
this may be reported. If no triallelic results are observed,
the increased risk of a mitotic non-disjunction event may
be reported. Mosaic findings should relate to the referral
indication where appropriate. Expert analysis can detect
second cell lines to a level of at least 20%, however,
mosaicism at lower levels may not be detected.
Where normal QF-PCR results are found in samples
referred with a high-risk NIPT result, it is recommended
that non-concordance of the QF-PCR with the NIPT result
is highlighted and a statement that the QF-PCR diagnostic
result supersedes the NIPT screening result should be
included in the report. In the case of AF samples with no
ultrasound anomalies, further analysis is not required. For
CVS samples, analysis of mesoderm (digested villi) is
recommended. In cases where CPM is a likely cause of the
discrepant result, ultrasound monitoring should be recom-
mended on the report.
The interpretation of QF-PCR results may be confused
by the presence of polymorphisms, such as primer site
polymorphisms (PSPs), CNV duplications or somatic
microsatellite variation (mutations) (SMMs).
● PSPs, e.g., SNPs within the primer sequences, may
cause reduced allele amplification and give an abnormal
or inconclusive result. Lowering the annealing tempera-
ture of the PCR reaction usually facilitates primer
hybridisation and allele amplification, and characterises
a PSP. However, in these cases the marker should not be
used for interpretation as amplification may not be
complete.
● Informative markers within a CNV duplication will give
an abnormal result at that locus, therefore single-marker
abnormal results must not be reported as consistent with
whole chromosome trisomy. If a single abnormal marker
result is flanked by normal markers and has been
previously reported in normal individuals then it does
not have to be reported. However, if the abnormal
marker is the most distal or proximal or has not been
reported in a normal individual then further studies are
recommended prior to interpretation. Parental studies or
array analysis may provide further information.
● SMMs [16] constitute rare events that present either as a
skewed allele ratio or three alleles in an A+ B= C
pattern. If a single marker gives a characteristic SMM
pattern or inconclusive biallelic ratio, this does not have
to be reported. Analysis of cultured cells may assist
interpretation as the proportion of cells with the novel
allele is likely to change.
If both normal and abnormal marker results are observed
for a single chromosome, it is recommended that further
investigations are carried out such as lowering the PCR
annealing temperature, testing an additional aliquot/cultured
cells, parental studies and/or array studies. Such a result
may represent a polymorphism of no clinical significance or
partial chromosome imbalance. If the result is not likely due
to a SNP, CNV or SMM then it should be reported.
Finally, QF-PCR cannot detect any changes that lie
outside the target sequence of the markers and will not
detect balanced rearrangements. As with all targeted tests,
even when no aberrations are detected, the possibility
remains that biological changes in that gene or chromoso-
mal region do exist but remain undetected.
MLPA-based techniques
MLPA is a semiquantitative PCR technique that relies on
ligation of specific probes on adjacent DNA sequences and
multiplex amplification of these probes [17, 18]. This
methodology allows for the detection of copy number (CN)
changes (deletions/duplications) and/or methylation status
in several types of disorders, including some that would
otherwise remain undetected without prior knowledge of the
molecular defect. Possible applications include the detection
of common aneuploidies, microdeletions/microduplications
in known syndromes, variants (and SNPs), subtelomere
screening, characterisation of marker chromosomes, or
determination of the methylation status of imprinted and
promotor regions [methylation-sensitive MLPA (MS-
MLPA)]. Commercial kits are available and are specific for
each application thus the most appropriate kit should be
used according to the referral reason (www.mrc-holland.
com). Where commercial kits are used, manufacturer’s
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instructions should be followed when preparing samples for
MLPA application, including the recommended DNA
extraction method.
Different types of tissues may be used such as CVS, AF
or foetal blood, as well as postnatal blood or buccal swab
samples. Processing uncultured AF and CVS samples for
MLPA analysis should follow the same procedures as
described above (see section Sample preparation). All the
samples in one assay should be prepared by the same
method to ensure assay consistency and allow appropriate
comparison between samples and normal controls. Blood
staining in an AF sample should be noted as there may be
MCC present. For CVS samples, analysis of mesoderm
(digested villi) is recommended due to the possibility of
CPM in the trophoblast.
When using MLPA for the first time, or when changing
the DNA extraction method or instruments used, it is
essential to perform internal validation of the MLPA tech-
nique. It is recommended that 16 DNA samples from
healthy individuals are used for this validation and the
standard deviation (SD) result of the experiment should be
< 0.10 for all probes.
A negative, a positive and three normal controls must be
included in each MLPA reaction. Peak areas in the elec-
trophoretogram should be used, after standardisation, for
evaluation of CN variation of specific genomic sequences in
each sample. Peak quality and quantitative data should be
assessed using specific software (e.g., PeakScanner, Cof-
falyser, GeneMapper, etc). Comparison of results should be
performed between samples of the same assay to avoid
intra-assay variation. For the reference samples, the SD of
all probes should be ≤ 0.1 and dosage quotients (DQ)
between 0.85 and 1.15. For the test samples, the SD of the
reference probes should be ≤ 0.1 and the DQ between 0.85
and 1.15.
Evaluation of CN variation should be performed using
peak areas in the electrophoretogram, after normalisation.
The DQ obtained therein are used for the interpretation of
results as follows: 0.85 < DQ < 1.15 indicates a normal
result; 1.35 < DQ < 1.55 indicates a heterozygous duplica-
tion; 1.70 < DQ < 2.20 indicates a triplication; 0.35 < DQ <
0.65 indicates a heterozygous deletion; DQ= 0 indicates a
homozygous deletion; all other DQ values indicate an
inconclusive result [19, 20].
A trisomy for a particular chromosome should be con-
sidered if at least four out of eight probe ratios for a certain
chromosome are ≥ 1.30 and the relative probe ratios for the
remaining four probes are close to 1.30. Monosomy X
should be considered if the probe ratios for X chromosome
probes are within the range of those of normal males and Y
signals are absent. If probe ratios for Y chromosome probes
are within the range for those of normal males and X
chromosome probes are ~2 times those of normal males 47,
XXY should be considered. On the other hand, if probe
ratios for Y chromosome probes are ~2 times those of
normal males and X chromosome probes are within the
range of those of normal male then 47,XYY should be
considered. If the relative probe signals for X chromosome
probes are ~2.5–3 times those of normal males and Y sig-
nals are absent 47,XXX should be considered. In cases
where a partial chromosome gain has occurred, a duplica-
tion of a specific region will result in a ratio > 1.30 of two
(or more) consecutive (and corresponding) probes. Addi-
tional studies should be used to confirm and interpret the
result.
For prenatal samples, it is recommended that chromo-
somes 13, 18 and 21 are always tested. If there is no pro-
tocol in place for routine testing of sex chromosomes, it is
recommended that one is available for samples referred with
ultrasound anomalies suggestive of Turner syndrome.
In MS-MLPA, most probes detect the methylation of the
first cytosine nucleotide in a single HhaI site within the
sequence detected by the probe (GmCGC). If methylation is
absent for this particular CpG-site, it does not necessarily
mean that the whole CpG island is unmethylated. It also
should be noted that methylation status may vary across
tissues (e.g., it is not recommended to be used in CVS) and
age groups. Determination of the methylation status
(detection of methylated and unmethylated regions) of
specific imprinted regions is performed simultaneously with
CN detection by carrying out a digestion step with a
methylation-sensitive endonuclease (HhaI) before the PCR
reaction. Absence or decrease of peak signals will reflect the
hybridisation of MS-MLPA probes that hybridise to
unmethylated target sequences, digested by HhaI (therefore
not amplified). This allows for the detection of CN eva-
luation. In contrast, the presence of peak signals result from
the hybridisation of MS-MLPA probes to methylated
sequences, undigested by HhaI and amplified. This allows
for evaluation of methylation changes. To determine the
methylation status of each MS-MLPA probe, the peak
pattern of each digested DNA samples should be compared
with the corresponding undigested sample. The methylation
profile of a test sample is assessed by comparing the probe
methylation percentages obtained on the test sample to the
percentages of the reference samples. In order to ensure
methylation analysis reliability, two criteria (additional to
the ones described in the beginning of this section) should
be met for all digested samples: the probe signal of the
‘digestion control probes’ should be 4% or less of the
corresponding probe signals in the undigested reactions;
and the DQ of the reference probes should be between 0.70
and 1.30. The comparison of undigested samples and nor-
mal controls for each probe allows for the CN evaluation
that should be performed as described above for ‘regular’
MLPA analysis. It is essential to include reference (positive
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as well as negative controls) samples in each run to ensure
assay consistency. Reliable MS-MLPA results should
yield SD < 10% for each probe when testing normal
samples.
Limitations of MLPA technology should be taken into
account when opting for this type of methodology and they
include:
● The test’s performance may be affected and compro-
mised by factors such as impurities in the DNA sample,
incomplete DNA denaturation, the use of insufficient or
too much sample DNA, the use of insufficient or
unsuitable reference samples, problems with capillary
electrophoresis or a poor data normalisation procedure.
● Target nucleic acid sequence polymorphisms may result
in impairment of probe hybridisation and amplification,
leading to decreased fragment signals and consequent
erroneous interpretation as a deletion. Sequence variants
may also be undetectable unless occurring in target sites
included in the probe kit/mix and/or in sites correspond-
ing to probe ligation points.
● MLPA does not allow for the detection of XXX
triploidy, mosaicism, MCC, chimeras nor the determi-
nation of zygosity in twin pregnancies, which leads to
the possibility of discrepant/false-negative results.
In cases with a clinical indication of triploidy where
an apparent female diploid result is obtained, it should
not be reported unless confirmed by another technique
(e.g., QF-PCR). In cases where MCC is suspected
(blood-stained AF or maternal decidua on CVS), as it is
not possible to distinguish between maternal and foetal
genotypes an alternative method (e.g., QF-PCR) is
recommended. Consequently, for prenatal and solid
tissue samples QF-PCR is considered a more appro-
priate technique.
● The presence of pseudomosaicism may not be detected
by MLPA, which would potentially result in a
misdiagnosis (false-positive or false-negative results).
● MLPA is also not able to detect any changes that lie
outside the target sequence of the probes and it cannot
detect balanced rearrangements. Even when no aberra-
tions are detected, the possibility remains that biological
changes in that gene or chromosomal region do exist but
remain undetected.
Follow-up analysis (e.g., karyotype) should be under-
taken following the detection of an aneuploidy to identify
structural rearrangements and assess the recurrence risk.
The same holds true for subtelomeric screening. Where
further confirmatory analysis of the original material is not
possible, parental karyotyping is recommended. For sam-
ples referred with ultrasound abnormalities, with a normal
MLPA result, array CGH, SNP-based array or karyotype
analysis is recommended. On the other hand, MLPA may
also be used for confirmatory purposes following FISH or
microarray studies. Where normal MLPA results are found
in samples referred with a high-risk NIPT result, it is
recommended that discrepancy of results is highlighted and
a statement that the MLPA diagnostic result supersedes the
NIPT screening result should be included in the report.
Where CPM is a possible cause of the discrepant CVS
result, ultrasound monitoring should be recommended on
the report.
As with the other tests described, MLPA results should
be reported using the latest ISCN and it is essential that the
kit name is given in the report. When obtaining DQ results
that repeatedly lie in the inconclusive range of values, the
report should state as much that a final result is pending a
subsequent analysis (e.g., array or karyotype).
Microarray-based techniques
Genome-wide microarray-based analysis (array) is used to
detect chromosomal imbalances at a significantly higher
resolution than routine cytogenetic analysis. Because of its
higher diagnostic yield, genome-wide array analysis is
recommended as a first-tier diagnostic test for patients with
ID, autism, neurodevelopmental disorders and/or congenital
anomalies. In prenatal diagnosis, array analysis is recom-
mended in the case of abnormal foetal structural ultrasound
anomalies.
There are several designs and array platforms available
containing at least 60,000 oligonucleotide probes onto
which a mix of a differentially labelled test and reference
DNA sample is hybridised. A diagnostic array platform
should achieve a resolution of at least 400–600 kb for pre-
natal [21, 22] and 200–400 kb for postnatal referrals of
developmental delay and congenital anomalies [23, 24].
bacterial artificial chromosome (BAC) array platforms are
therefore no longer considered suitable for routine pre- and
postnatal diagnostics. Many of the array platforms nowa-
days make use of SNP oligonucleotide probes, often in
combination with the aforementioned oligonucleotide CN
probes. Depending on the type and design of the array
platform, one-labelled DNA sample (either test or reference)
is hybridised onto a SNP-based array. The digital array data
from each SNP-based array experiment can subsequently be
selected to perform so-called ‘in silico’ array CGH analysis.
With genome-wide SNP-based array analysis it is possible
to not only determine the relative amount of numerous
DNA targets to detect CNVs (as in Oligo arrays), but also to
genotype each DNA target encompassing a SNP. The
genotype information of the SNPs in a DNA sample enables
the detection of CN neutral changes, absence of hetero-
zygosity (AOH), and thereby, after suitable follow-up
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testing, the possible identification of recessive disease gene
variants, mosaic aneuploidy or uniparental disomy (UPD).
Patient–parent (trio) information analysis can be used to
screen for the presence of any form of chromosomal UPD in
the patient and/or to determine the parental origin of a de
novo CNV. Moreover, the outcome of a genotype analysis
(which can be performed with any combination of two or
three array datasets) can also be used as a final quality
control by ruling out potential sample mismatches due to
false paternity or sample mix-up.
The laboratory should clearly state in their laboratory
documents the theoretical resolution of their array platform,
determined in large by the number of the probes on the
array and the spacing between them. Because many of the
probes are not spaced uniformly it is better, if possible and
applicable, to refer to the ‘average’ resolution, differentiat-
ing between the targeted and the backbone resolution.
Inherent to the structure of the human genome, this average
resolution is not achieved for all regions, such as the
repetitive sequences in the centromeric and heterochromatic
regions. As a consequence, supernumerary marker chro-
mosomes that do not contain euchromatic material will not
be detected by array analysis.
The practical resolution of an array expresses the ability to
detect aberrations of a given (minimum) size. The detection
criteria (i.e., the minimum size and number of probes to call
a CNV), as well as the reporting criteria (i.e., size and sort of
a CNV, as well as its gene content) should also be included
in the laboratory standard operating documents.
Microarrays may be applied for a number of indications
and sample types. For postnatal indications, DNA is mostly
obtained from EDTA blood, but other tissues such as buccal
swab cells, Epstein-Barr virus (EBV)-transformed cells and
(un)cultured fibroblasts may also be used. For prenatal array
analysis, DNA is isolated from chorionic villus cells,
amniocytes or foetal blood, either cultured or uncultured.
Microarray analysis of DNA prepared from products of
conception and foetal tissues is used to investigate the cause
of miscarriage and foetal abnormality. The minimum con-
centration and amount of input DNA for array depends on
the array platform used, but the DNA concentration is
preferably ≥ 70 ng/µl.
Each array experiment should meet the laboratory’s
defined minimally required quality criteria, such as SD of
the intensity ratios, SNP-QC (quality of the SNP allele
data), and 'waviness' or GC (nucleotides) metric [23, 25].
Determining the pathogenicity of CNVs relies heavily on
the frequency information from healthy control cohorts and
databases with previously reported clinically relevant
CNVs. In addition to the host laboratories’ own datasets and
national registries, there are several public databases and
internet resources with genotype and phenotype information
that can be used for array data interpretation [26].
In line with the classification of nucleotide variants, it is
recommended to classify CNVs into five classes based on
the degree of likelihood of pathogenicity, which for CNVs
is predominantly based on the frequency differ-
encesbetween the general population and affected indivi-
duals [26, 27]:
- Class 1: Benign;
- Class 2: Likely benign;
- Class 3: Uncertain clinical relevance (uncertain
significance);
- Class 4: Likely pathogenic;
- Class 5: Pathogenic.
In order to correctly assess the clinical relevance of a
CNV one needs to take into account the following inheri-
tance models and other aspects [28, 29]:
- Dominant de novo or inherited (phenotype information
of parents is crucial);
- Recessive; compound heterozygote or homozygous
variant;
- X-linked;
- Imprinted genes;
- Mosaicism; in patient or parent;
- Two-hit CNV model;
- CNV in a non-genic region containing a regulatory
sequence of a nearby disease gene;
- Genomic position of a CN gain; follow-up testing by
region-specific FISH metaphase analysis may be helpful to
determine whether the gain is due to a tandem duplication, an
insertion elsewhere in the genome or a supernumerary marker.
Prenatally a CNV should be reported if it is consistent
with the ultrasound findings as it will possibly affect the
management of the pregnancy or a future individual or the
family and is actionable. However, care should be taken
when interpreting the identification of known pathogenic
CNVs in a prenatal context in the absence of ultrasound
anomalies as there is clinical ascertainment bias within the
postnatal population [30].
The array results should be summarised in the latest ISCN
and described in a clear and concise way, using correct ter-
minology (dominant, recessive, heterozygous, homozygous,
hemizygous, etc.). Class 1 and 2 variants are not to be
included in the final report, unless, for example, it concerns a
benign CN loss encompassing a recessive disease gene
matching the clinical phenotype of the patient. One such
example is a common 130-kb CN loss in 2q13 encompassing
the NPHP1 gene. Even though a heterozygous loss is fre-
quently encountered in healthy individuals and hence classi-
fied as a (likely) benign CNV, a homozygous loss will cause
nephronophthisis type I, a recessive cystic kidney disease
(OMIM #256100). The accuracy of the CNV size(s) reported
should be in line with the platform’s practical resolution. If
appropriate, the CNV’s clinically relevant genes related to the
referral reason and/or clinical features of the patient analysed
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are mentioned in the report. It is recommended to clearly state
whether or not the reported finding could be causative for the
clinical phenotype of the patient. In the case of a clearly
defined associated phenotype, not only the respective gene(s)
or established deletion/duplication region should be stated,
but it is helpful to also include more information/references,
i.e., the syndrome name (if applicable), respective OMIM
number(s) and/or recent and relevant (review) papers for
additional information. References may be added to the
report, as long as these are not too old or generic, and should
be cited in a format that allows the reader to easily identify the
original article. A schematic representation of the aberrant
region(s) and its gene content may be included for illustration.
It is good practice to suggest suitable follow-up testing in
patient and/or parents and clearly state, which samples are
required for these specific test(s).
AOH should only be mentioned in the report if sig-
nificantly increased from normal [31]:
- A single region of homozygosity (ROH) ≥ 10Mb,
which may be an indication for uniparental heterodisomy
(UPD) or identity by descent (IBD);
- > 1% homozygous stretches on the autosomal genome
(excluding X and Y), which may be an indication for par-
ental consanguinity, hence an increased risk for a mutated,
recessive disease gene.
It is recommended to only specify increased homo-
zygosity in the ISCN description if it involves a single
chromosome. If multiple chromosomes show significant
homozygous stretches, mentioning it in the report would be
more appropriate, e.g., a total of 145Mb of homozygous
stretches were detected (~4.8% of the autosomal genome).
It should be noted that increased homozygosity can also be
detected in unaffected individuals (but with a lower inci-
dence) and is not in itself pathogenic, but adequate follow-
up testing may identify the actual disease cause (i.e., UPD
or a mutated recessive disease gene) if increased homo-
zygosity is detected in a patient. The individual laboratory
reporting criteria for AOH for both prenatal and postnatal
referrals should also be clearly included in the laboratory
standard operating documents.
Genome-wide array analysis cannot detect balanced
rearrangements (including those that involve hetero-
chromatin), small supernumerary marker chromosomes,
low-level mosaicism or a nucleotide variant. Only SNP-
based arrays can detect ploidy changes and UPD so when
using array platforms with no or a limited number of SNPs
these limitations should be included in the report.
Next-generation sequencing (NGS) for CNV
detection
NGS is a general term for a variety of methods and it has a
number of applications, including NIPT for prenatal
aneuploidy screening and whole-exome sequencing (WES),
which are both used in a growing number of genome
diagnostic laboratories. The targeted capture of exomes in
combination with NGS based on short-read length tech-
nology (50–300 bp reads) and high-density coverage ( >
30 × ) of the captured fragments makes WES a promising,
efficient and cost-effective approach for genetic testing. The
focus on the exome (~50Mb) is justified, because thus far,
approximately 85% of disease-causing variants have been
identified in exons or at splice-junction boundaries in
introns. In addition to sequence variants, structural variants
or CNVs can also be detected in WES data, which increases
the diagnostic yield. Although widespread application is
currently prohibited both by cost and the requirement for
complex algorithms and data analysis pathways, it is pre-
dicted that this will become a standard approach for genetic
diagnosis in coming years [32].
The interpretation of CNV in NGS data follows the same
rules as mentioned under array-based techniques (see sec-
tion Microarray-based techniques).
Whole-exome sequencing
Each WES experiment should meet the laboratory’s defined
and documented minimally required quality criteria,
including base calling, mapping, coverage analysis and
variant calling, as detailed in Weiss et al. [33], Aziz et al.
[34] and Matthijs et al. [35].
Validation of a CNV in exome data by genome-wide
array analysis or another suitable technique is highly
recommended in case a finding is based on a limited number
of aberrant targets and/or an unexpected finding is
encountered, i.e., a large chromosomal imbalance in a
person without ID or an apparently mosaic finding.
The analysis, interpretation and reporting of CNV in
exome data should be in line with the referral reason, as well
as with the informed consent – i.e., permission for gene panel
(targeted) only or including ‘whole exome’. Relevant CNVs
detected in exome data should be summarised in a cytoge-
nomic description according to the latest ISCN. These rele-
vant CNV in exome data results should be described in the
report in a clear and concise way as mentioned under array-
based techniques. The results from nucleotide variant
and CNV analysis in exome data are obtained from a single
experiment and must therefore be combined in a single report.
WES data analysis cannot detect balanced rearrangements
or low-level mosaicism. Ploidy changes may only be
detectable if suitable tools are employed in an adequate way
and these limitations should be included in the exome report.
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